Neutrolin Executive Committee

Our Neutrolin Executive Committee is composed of physicians with special expertise in hemodialysis, vascular access and catheter-related bloodstream infections (CRBI). These outstanding physicians will provide the high-level critical thinking and clinical trial experience that will allow CorMedix to optimally design and execute the Neutrolin Pivotal Clinical Trial.

The Executive Committee includes:

Michael Allon, M.D.

Dr. Allon is Professor of Medicine at the University of Alabama. Dr. Allon was the Principal Investigator of the pilot Neutrolin study in the U.S., and is widely recognized as an expert in hemodialysis vascular access and CRBI. He was also a member of the Infectious Disease Society of America Working Group on CRBI, and an author of the practice guidelines.

Alfred K. Cheung, M.D.

Dr. Cheung is Professor of Medicine, Chief of Division of Nephrology & Hypertension, and Executive Director of Dialysis Program at the University of Utah. Dr. Cheung is recognized as an expert in hemodialysis, and as a clinical trialist in CKD and hemodialysis. He also has an active laboratory interest focused on the development of therapeutics to prevent hemodialysis vascular access stenosis.

Charmaine Lok, M.D.

Dr. Lok is Medical Director of the Renal Management and Hemodialysis Vascular Access Programs, University of Toronto Health Network. Dr. Lok is widely recognized as an expert in hemodialysis vascular access and CRBI.

Michele Mokrzycki, M.D.

Dr. Mokrzycki is Professor of Clinical Medicine, Albert Einstein College of Medicine. Dr. Mokrzycki is an expert on the use and outcomes of CVCs in hemodialysis patients as well as CRBI.

©2011 CorMedix Inc.